These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 25112553)

  • 1. [Patient's care and management of dyslipidemia in type 2 diabetic patients in the clinical practice in Spain: The LIPEDIA study].
    Pascual Fuster V; Ruiz Olivar E; Pintò Sala X;
    Clin Investig Arterioscler; 2015; 27(2):45-56. PubMed ID: 25112553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Patient's care and management of dyslipidemia at discharge after an acute coronary syndrome in the clinical practice in Spain: The SINCOPA study].
    Murga N; Ruiz E; Pascual V;
    Clin Investig Arterioscler; 2015; 27(6):272-9. PubMed ID: 26100329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of atherogenic dyslipidemia in the primary care setting in Spain.
    Díaz Rodríguez Á; Blasco Valle M; Mantilla Morató T; Capón Alvarez J; Rodríguez de Miguel M; Rodríguez-Fortúnez P; Prada-Marcos C; Orera-Peña ML
    Clin Investig Arterioscler; 2019; 31(5):203-209. PubMed ID: 31320121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
    Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
    BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical recommendations for the management of cardiovascular risk associated with atherogenic dyslipidemia, with special attention to residual risk. Spanish adaptation of a European Consensus of Experts.
    Grupo de trabajo de Dislipemia Aterogénica de la Sociedad Española de Arteriosclerosis y Grupo Europeo de Expertos
    Clin Investig Arterioscler; 2017; 29(4):168-177. PubMed ID: 28433209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The gap between the current dyslipidemia guidelines and the physicians' treatment targets in patients with type 2 diabetes in Turkey.
    Kahya Eren N; Harman E; Dolek D; Emren S; Tütüncüoğlu AP; Nazli C; Ergene O
    Minerva Cardioangiol; 2014 Jun; 62(3):287-95. PubMed ID: 24831765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol].
    Brea Hernando ÁJ
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():3-6. PubMed ID: 25043539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Achievement of therapeutic objectives].
    Mantilla T
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():20-4. PubMed ID: 25043543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy.
    Aguiar C; Alegria E; Bonadonna RC; Catapano AL; Cosentino F; Elisaf M; Farnier M; Ferrières J; Filardi PP; Hancu N; Kayikcioglu M; Mello E Silva A; Millan J; Reiner Ž; Tokgozoglu L; Valensi P; Viigimaa M; Vrablik M; Zambon A; Zamorano JL; Ferrari R
    Atheroscler Suppl; 2015 Sep; 19():1-12. PubMed ID: 26315511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Perspective of primary care physicians on the management of dyslipidaemia in patients without atherosclerotic cardiovascular disease: a cross-sectional study].
    Fuster VP; Escobar C
    Rev Med Chil; 2023 Sep; 151(9):1143-1152. PubMed ID: 39093151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-lowering pharmacotherapy in Central and Eastern European countries in cardiovascular prevention: self-reported prescription patterns of primary care physicians.
    Tomasik T; Windak A; Seifert B; Kersnik J; Kijowska V; Dubas K
    J Cardiovasc Pharmacol Ther; 2013 May; 18(3):234-42. PubMed ID: 23277158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
    Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
    Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].
    Pérez A
    Endocrinol Nutr; 2010 Dec; 57(10):457-9. PubMed ID: 20688585
    [No Abstract]   [Full Text] [Related]  

  • 14. [Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease].
    Pérez A; González Blanco C; Hernández-Presa MÁ; Chaves J
    Endocrinol Nutr; 2011; 58(6):283-90. PubMed ID: 21641286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of older patients with dyslipidemia].
    González DF
    Semergen; 2014 May; 40 Suppl 1():17-21. PubMed ID: 25263639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy studies].
    Pedro-Botet J; Flores-Le Roux JA
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():17-9. PubMed ID: 25043542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Indications for the combination of pravastatin and fenofibrate according to the cardiovascular risk level. Common clinical situations].
    Pintó X
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():35-9. PubMed ID: 25043546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Guidelines for the management of dyslipidemia].
    Díaz Rodríguez Á;
    Semergen; 2014 Sep; 40 Suppl 4():19-25. PubMed ID: 25595349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of statins in managing diabetic dyslipidemia.
    Toth PP
    J Fam Pract; 2010 May; 59(5 Suppl):S23-9. PubMed ID: 20544054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
    Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
    Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.